Trial Profile
Effect of Anagliptin and Sitagliptin on Low-density Lipoprotein Cholesterol in Patients With Type 2 Diabetes and Cardiovascular Risk Factors: Randomized Controlled Trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Anagliptin (Primary) ; Sitagliptin (Primary)
- Indications Cardiovascular disorders; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms REASON
- 03 Feb 2019 Status changed from active, no longer recruiting to completed.
- 10 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 01 Feb 2018 Study Design published in the Cardiovascular Drugs and Therapy.